MAPT and Alzheimer disease: The evidence suggests that the effective use of tau PET can differentially diagnose AD [14,15], forecast neurodegeneration [16,17,18], and predict future cognitive decline [19,20,21], all of which position it as the optimal complementary tool for the study and staging of AD.